Post Archive by Day

Weight reduction of at least 10 percent occurred in 46 to 75 percent receiving orforglipron by week 36

Increased risks included heart failure, cystitis, glucose dysregulation, iron deficiency anemia, poisoning, self-harm

However, weight loss by 12 months was not significantly different for time-restricted eating, calorie restriction

Significant risk reduction in primary end point of composite of cardiovascular death nonfatal myocardial infarction, nonfatal stroke, coronary revascularization